



LOMA LINDA UNIVERSITY
Cancer Center

July 26, 2011

Re: Accrual of Unrepresented Minority Women to Breast Cancer Clinical Trials in the Inland Empire

Dear Oncologist:

Ethnic minority women have poorer cancer related outcomes and they are currently underrepresented in cancer clinical trials. The age adjusted incidence and mortality rates for breast cancer are higher in Riverside and San Bernardino Counties than the statewide average. During the 10 years of enrollment, only 26.7% minority patients were enrolled into clinical trials, in contrast with the 59% of ethnic minority women living in the Inland Empire.

We are currently conducting a project to improve clinical trial enrollment rate of underserved minority women in the Inland Empire. This project is funded by Susan G. Komen for the Cure, Inland Empire Affiliate. The ultimate goal is to decrease disparities in breast cancer care, improve the cure rate and quality of life and eventually decrease the breast cancer burden particularly in our underserved minority groups in Inland Empire.

We are currently conducting the following breast cancer clinical trials:

1. NSABP-B43 (NCT00769379): a randomized phase III trial is studying radiation therapy to see how well it works compared with or without trastuzumab in treating women with DCIS who have undergone lumpectomy.
2. SWOG-S0500 (NCT00382018): a randomized phase III trial is studying treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy.
3. CALGB-40502 (NCT00785291): A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
4. Z-ACT 1 (NCT01129336): This study will evaluate zoledronic acid's anti-cancer effects using Circulating Tumor Cell measurements in patients with newly diagnosed HER2-negative metastatic breast cancer.

5. SWOG S-0800: A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel(Nab-Paclitaxel) with or without Bevacizumab, either proceed by or followed by Q2 week Doxorubicin and cyclophosphamide plus Pegfilgrastim as Neoadjuvant Therapy for inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer

7. TDM4370g: A Randomized, Multicenter, Phase III Study of the Efficacy and Safety of Transtuzumab-MCC-DM1 vs. Capcitabine and lapatinib in Patietns with HER2- Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab-Based Therapy)

8. SWOG S-1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer according to Recurrence Score (RS).

9. NSABP FB-7: A phase II randomized clinical trial evaluating Neoadjuvant therapy regimens with weekly paclitaxel and neratinib or trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-postivie breast cancer.

For details of the key eligibility and exclusion criteria for these studies, please visit: www.clinicaltrials.gov or www.llucc.org

To refer a patient or discuss above studies in more detail, please contact our call center at 909-558-2262. If any patient chooses to participate, we will obtain informed consent. In referring patients to us, please be assured that our involvement will be strictly study related.

Sincerely,

Yuan Yuan, M.D., Ph.D.
Loma Linda University Cancer Center
Tel: (909) 558-4000 ext. 87140
Fax: (909) 558-5939
Pager yyuan@my2way.com
Email: yyuan@llu.edu